Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

News

The latest news, stories and exciting findings from across the Oxford cancer research community

University's RadCam library highlighted in yellow
David Church

Dr David Church awarded Senior Cancer Research Fellowship from Cancer Research UK

David’s research will focus on immune dysregulation in colorectal and endometrial pre-cancers and cancers.

Dr Parinaz Mehdipour awarded CRUK Early Detection and Diagnosis Primer Award

Ludwig Oxford’s Parinaz Mehdipour has been awarded a CRUK Early Detection and Diagnosis Primer to identify circular RNA biomarkers for the early detection of normal colon cell transformation into precancerous and colorectal cancer states

Oxford Cancer Hosts Inaugural Oesophagogastric Cancer Centre of Excellence Symposium

The inaugural Oxford Oesophagogastric Cancer Centre of Excellence Symposium took place on Tuesday, 25th February, at Lincoln College, Oxford. The event brought together collaborators from across Oxford and further afield who share a commitment to advancing research into and treatment for oesophagogastric cancer.

OCION: In conversation with Tamsin Cargill

Through the Oxford Cancer Immuno-Oncology Network (OCION), we aim to apply Oxford's leading expertise in fundamental immunology to enable more patients, with a wide range of cancer types, to benefit safely from tailored immunotherapy use. We sat down with OCION Pump Prime awardee - Dr. Tamsin Cargill - to discuss her research.

Vegetables

Lifestyle and environmental factors affect health and ageing more than our genes

A new study led by researchers from Oxford Population Health has shown that a range of environmental factors have a greater impact on health and premature death than our genes. The researchers used data from nearly half a million UK Biobank participants to assess the influence of 164 environmental factors and genetic risk scores for 22 major diseases (including some cancers) on ageing, age-related diseases, and premature death.

Pancreatic cancer immune map provides clues for precision treatment targeting

New research - published today in Nature Communications - shows why there are differences in prognosis between different pancreatic tumours and identifies potential avenues for improved treatment approaches.

Cancer patient in a bed talking to a nurse

World Cancer Day 2025: United By Unique

On World Cancer Day, Dr Sharon Tonner reflects on the theme 'United by Unique', sharing how the team in the Nuffield Department of Primary Care and Health Sciences is navigating and addressing the need for patient-centered care and inclusive, equitable research.

Colorectal cancer being highlighted in the body

Bowel cancer prediction test for IBD patients 90% accurate

Researchers in NDM have authored a collaborative study which explored a new method for detecting bowel cancer, which was found to be more than 90% accurate at predicting which higher-risk people will develop this type of cancer in the future.

Immunotherapy drugs attacking a cancer cell

Early-Career Researchers Awarded Competitive Funding for Pioneering Cancer Studies

Two early-career postdoctoral researchers at the Department of Oncology - Ahmet Hazini and Esther Ng - have secured funding to deliver pioneering research projects that aim to advance the field of cancer immunotherapy.

Oxford and GSK launch £50million immuno-prevention programme to advance novel cancer research

Global biopharma company GSK invests up to £50 million in a collaboration with Oxford to advance the understanding of how cancer develops, which could inform future development of vaccines to prevent cancer.

Headshot of Audrey Gerard

OCION: In conversation with Audrey Gerard

Through the Oxford Cancer Immuno-Oncology Network (OCION), we aim to apply Oxford's leading expertise in fundamental immunology to enable more patients, with a wide range of cancer types, to benefit safely from tailored immunotherapy use. We sat down with OCION Pump-Prime Awardee, Associate Professor Audrey Gerard, to discuss her research.

Blood test tubes

Oxford researchers develop blood test to enable early detection of multiple cancers

Oxford University researchers have unveiled a new blood test – powered by machine learning – which shows real promise in detecting multiple types of cancer in their earliest stages, when the disease is hardest to detect.

White blood cell surrounded by red blood cells

Alethiomics – using Artemis to hunt down blood cancers

Spin-out company Alethiomics, focused on the development of innovative treatments for blood cancers, is Oxford through-and-through. Founded by Clinician Scientists who run neighbouring laboratories at the University’s MRC Weatherall Institute of Molecular Medicine, seed financed by Oxford Science Enterprises and located at the BioEscalator, the company’s early years have been immersed in the Oxford innovation ecosystem.

A longitudinal section of fetal femur with multiplex immunofluorescent staining, showing CD34 in red and VEGFR2 in green.

Researchers provide a perspective on mapping the bone marrow using new spatial transcriptomic technologies

RDM researchers have outlined the potential benefits and limitations of new spatial transcriptomic technologies for mapping the bone marrow in patients with blood cancer.

S:CORT Logo

Predicting Response to Rectal Cancer Treatment through the S:CORT consortium

Recent research from the S:CORT team spanning three publications has identified key biomarkers and treatment strategies that predict and enhance effectiveness of radiotherapy in rectal cancer treatment.

OCION: In conversation with Adán Pinto-Fernández

Through the Oxford Cancer Immuno-Oncology Network (OCION), we aim to apply Oxford's leading expertise in fundamental immunology to enable more patients, with a wide range of cancer types, to benefit safely from tailored immunotherapy use. We sat down with Dr. Adán Pinto-Fernández to discuss his research.

Register for the 2025 Oxford Cancer Symposium!

The Oxford Cancer Symposium supported by the CRUK Oxford Centre is the crowning event in the Oxford Cancer calendar. With approximately 300 people attending in person each year, it provides an opportunity for our members to network and build new collaborations.

University of Oxford unveils new vaccine development partnership

Oxford Cancer, the Oxford Vaccine Group and the Pandemic Sciences Institute have announced a new collaboration with Belgian Biotech Innovator, Univercells.

MyMelanoma logo on a white background

MyMelanoma study selected to join NHS DigiTrials initiative

Three projects – including the Oxford-led MyMelanoma study - have been selected to join an NHS initiative, which aims to sign up tens of thousands of volunteers over the next two years to help improve the diagnosis and treatment of cancer patients.

OCION logo on a white background

2024 OCION Pump Prime Awardees Named

Congratulations to the 2024 OCION Pump Prime Awardees, funded by the CRUK Oxford Centre and NIHR Oxford BRC

Load More